Integrated genomic and molecular characterization of cervical cancer. Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services, HudsonAlpha Institute for Biotechnology, ILSbio, LLC, Indiana University School of Medicine, Institute of Human Virology, Institute for Systems Biology, International Genomics Consortium, Leidos Biomedical, Massachusetts General Hospital, McDonnell Genome Institute at Washington University, Medical College of Wisconsin, Medical University of South Carolina, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NantOmics, National Cancer Institute, National Hospital, Abuja, Nigeria, National Human Genome Research Institute, National Institute of Environmental Health Sciences, National Institute on Deafness &Other Communication Disorders, Ontario Tumour Bank, London Health Sciences Centre, Ontario Tumour Bank, Ontario Institute for Cancer Research, Ontario Tumour Bank, The Ottawa Hospital, Oregon Health &Science University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SRA International, St Joseph's Candler Health System, Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University, Research Institute at Nationwide Children's Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of Bergen, University of Texas MD Anderson Cancer Center, University of Abuja Teaching Hospital, University of Alabama at Birmingham, University of California, Irvine, University of California Santa Cruz, University of Kansas Medical Center, University of Lausanne, University of New Mexico Health Sciences Center, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, University of Pittsburgh, University of São Paulo, Ribeir ão Preto Medical School, University of Southern California, University of Washington, University of Wisconsin School of Medicine &Public Health, Van Andel Research Institute, Washington University in St Louis (2017) Nature 543: 378-384 ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Arteaga CL, Engelman JA (2014) Cancer Cell 25: 282-303 Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Carver RS, Stevenson MC, Scheving LA, Russell WE (2002) Gastroenterology 123: 2017-27 DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Zhu S, Belkhiri A, El-Rifai W (2011) Gastroenterology 141: 1738-48.e1-2 ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS (2013) J Clin Invest 123: 4329-43 Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA (2008) J Clin Invest 118: 2609-19 The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS (2012) Proc Natl Acad Sci U S A 109: 221-6 Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL (2012) Proc Natl Acad Sci U S A 109: 2718-23 Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL (2011) Proc Natl Acad Sci U S A 108: 5021-6 Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Cancer Res 73: 4075-85 Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL (2009) Cancer Res 69: 4192-201 HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS (2012) Cancer Res 72: 2672-82 An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA (2013) Cancer Res 73: 6024-35 Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL (2013) Cancer Res 73: 6013-23 ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL (2011) Cancer Res 71: 3941-51 The ErbB3 receptor tyrosine kinase negatively regulates Paneth cells by PI3K-dependent suppression of Atoh1. Almohazey D, Lo YH, Vossler CV, Simmons AJ, Hsieh JJ, Bucar EB, Schumacher MA, Hamilton KE, Lau KS, Shroyer NF, Frey MR (2017) Cell Death Differ 24: 855-865 Analysis of ErbB receptors in pulmonary carcinoid tumors. Rickman OB, Vohra PK, Sanyal B, Vrana JA, Aubry MC, Wigle DA, Thomas CF (2009) Clin Cancer Res 15: 3315-24 Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J (2013) Clin Cancer Res 19: 3078-87 Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL (2013) Clin Cancer Res 19: 5390-401 Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL (2013) Clin Cancer Res 19: 610-9 Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS (2016) Oncogene 35: 1143-52 H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL (2010) Oncogene 29: 5193-203 Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Giltnane JM, Moeder CB, Camp RL, Rimm DL (2009) Cancer 115: 2400-9 Hepatic expression of ErbB3 is repressed by insulin in a pathway sensitive to PI-3 kinase inhibitors. Carver RS, Mathew PM, Russell WE (1997) Endocrinology 138: 5195-201 Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors. Hao J, Galindo CL, Tran TL, Sawyer DB (2014) Biochem J 458: 335-41 Insulin regulates heregulin binding and ErbB3 expression in rat hepatocytes. Carver RS, Sliwkowski MX, Sitaric S, Russell WE (1996) J Biol Chem 271: 13491-6 Analytic variability in immunohistochemistry biomarker studies. Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL (2010) Cancer Epidemiol Biomarkers Prev 19: 982-91 Update on HER1-3 in advanced non-small-cell lung cancer. Horn L, Lovly C (2012) J Thorac Oncol 7: S369-71 Targeting HER1/EGFR: a molecular approach to cancer therapy. Arteaga C (2003) Semin Oncol 30: 3-14 Embryo-uterine interactions via the neuregulin family of growth factors during implantation in the mouse. Brown N, Deb K, Paria BC, Das SK, Reese J (2004) Biol Reprod 71: 2003-11 ErbB2 and ErbB3 regulate recovery from dextran sulfate sodium-induced colitis by promoting mouse colon epithelial cell survival. Zhang Y, Dubé PE, Washington MK, Yan F, Polk DB (2012) Lab Invest 92: 437-50 Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL (2013) PLoS One 8: e71518 Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Lebrasseur NK, Coté GM, Miller TA, Fielding RA, Sawyer DB (2003) Am J Physiol Cell Physiol 284: C1149-55 Dexamethasone modulates ErbB tyrosine kinase expression and signaling through multiple and redundant mechanisms in cultured rat hepatocytes. Scheving LA, Buchanan R, Krause MA, Zhang X, Stevenson MC, Russell WE (2007) Am J Physiol Gastrointest Liver Physiol 293: G552-9 Loss of hepatocyte EGFR has no effect alone but exacerbates carbon tetrachloride-induced liver injury and impairs regeneration in hepatocyte Met-deficient mice. Scheving LA, Zhang X, Stevenson MC, Threadgill DW, Russell WE (2015) Am J Physiol Gastrointest Liver Physiol 308: G364-77 Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis. Scheving LA, Zhang X, Stevenson MC, Weintraub MA, Abbasi A, Clarke AM, Threadgill DW, Russell WE (2015) Am J Physiol Gastrointest Liver Physiol 309: G942-54 Neuregulin-1β regulation of embryonic endothelial progenitor cell survival. Safa RN, Peng XY, Pentassuglia L, Lim CC, Lamparter M, Silverstein C, Walker J, Chen B, Geisberg C, Hatzopoulos AK, Sawyer DB (2011) Am J Physiol Heart Circ Physiol 300: H1311-9 The expression of neuregulin and erbB receptors in human skeletal muscle: effects of progressive resistance training. LeBrasseur NK, Mizer KC, Parkington JD, Sawyer DB, Fielding RA (2005) Eur J Appl Physiol 94: 371-5 Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL (2006) Genesis 44: 477-86
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.